Bile liquid biopsy in biliary tract cancer

Liu, Fusheng; Hao, Xingyuan; Liu, Bin; Liu, Songmei; Yuan, Yufeng

doi:10.1016/j.cca.2023.117593

Cited by 6 publications

(2 citation statements)

References 174 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, various emerging analytical methods for extracellular vesicles (EVs), nucleic acids, proteins, and metabolites in bile have been developed as potential biomarkers for BTC diagnosis [88]. For example, circular RNA (Circ-CCAC1) in serum-derived or bilederived EVs has a diagnostic role, with an AUC of 0.857 [89].…”

Section: Liquid Biopsy Based On Bile Samplesmentioning

confidence: 99%

Recent Advancement in Diagnosis of Biliary Tract Cancer through Pathological and Molecular Classifications

Lee,

Song

2024

Cancers

View full text Add to dashboard Cite

Biliary tract cancers (BTCs), including intrahepatic, perihilar, and distal cholangiocarcinomas, as well as gallbladder cancer, are a diverse group of cancers that exhibit unique molecular characteristics in each of their anatomic and pathological subtypes. The pathological classification of BTCs compromises distinct growth patterns, including mass forming, periductal infiltrating, and intraductal growing types, which can be identified through gross examination. The small-duct and large-duct types of intrahepatic cholangiocarcinoma have been recently introduced into the WHO classification. The presentation of typical clinical symptoms, as well as the extensive utilization of radiological, endoscopic, and molecular diagnostic methods, is thoroughly detailed in the description. To overcome the limitations of traditional tissue acquisition methods, new diagnostic modalities are being explored. The treatment landscape is also rapidly evolving owing to the emergence of distinct subgroups with unique molecular alterations and corresponding targeted therapies. Furthermore, we emphasize the crucial aspects of diagnosing BTC in practical clinical settings.

show abstract

Section: Liquid Biopsy Based On Bile Samplesmentioning

confidence: 99%

Recent Advancement in Diagnosis of Biliary Tract Cancer through Pathological and Molecular Classifications

Lee,

Song

2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Certain proteins and active substances in bile duct cancer cells, including some tumor markers, may enter the bile through paracrine or autocrine pathways [4]. Therefore, direct detection of tumor markers in bile components may provide certain clinical value for the early diagnosis and disease progression of bile duct cancer [5].…”

Section: Introductionmentioning

confidence: 99%

Bile-derived cfDNA of syncytin-1 and SLC7A11 as a potential molecular marker for early diagnosis of cholangiocarcinoma

He,

Qian,

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Bile circulating free DNA (cfDNA) as a novel liquid biopsy method for the early clinical diagnosis of cholangiocarcinoma (CCA) has been less reported. Methods: We collected bile samples from 51 patients with CCA and 48 patients with gallstones at Shandong Provincial third Hospital from September 2022 to December 2023. We quantified bile cfDNA of syncytin-1 and SLC7A11,calculated the correlation bySpearman rank correlation, plotted Receiver Operating Characteristic (ROC) curves, and compared the Area Under Curve (AUC) values to explored early diagnostic utility in patients. Results: We first found the bile cfDNA of syncytin-1 and SLC7A11 levels in CCA were higher than in gallstones (p < 0.001; p < 0.001). And there was significant correlation between syncytin-1 and SLC7A11 expression (Spearman ’r = 0.458, p < 0.001). The AUC of bile cfDNA of syncytin-1 was 0.891(specificity of 90.2% and sensitivity of 75.0%), the AUC of bile cfDNA of SLC7A11 was 0.793 (specificity of 80.4% and sensitivity of 72.9%), and combination of bile cfDNA of syncytin-1/SLC7A11/CA19-9 markers improved diagnostic efficiency in CCA patients (AUC:0.901, p < 0.001). Conclusion: The bile cfDNA of syncytin-1 and SLC7A11 was high expression in cholangiocarcinoma, which may be used as a novel biomarker for early diagnosis.

show abstract

The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic Significance

Macias,

Kanzaki,

Berasain

et al. 2024

The American Journal of Pathology

View full text Add to dashboard Cite

Bile liquid biopsy in biliary tract cancer

Cited by 6 publications

References 174 publications

Recent Advancement in Diagnosis of Biliary Tract Cancer through Pathological and Molecular Classifications

Recent Advancement in Diagnosis of Biliary Tract Cancer through Pathological and Molecular Classifications

Bile-derived cfDNA of syncytin-1 and SLC7A11 as a potential molecular marker for early diagnosis of cholangiocarcinoma

The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic Significance

Contact Info

Product

Resources

About